1
|
Chandra Doval D, Mehta A, Somashekhar SP, Gunda A, Singh G, Bal A, Khare S, Prakash V Serkad C, Adinarayan M, Krishnamoorthy N, Vijay DG, Anantakrishnan R, Bhattacharyya GS, Bakre MM. The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin. Breast 2021; 59:1-7. [PMID: 34098459 PMCID: PMC8187842 DOI: 10.1016/j.breast.2021.05.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 05/13/2021] [Accepted: 05/24/2021] [Indexed: 11/16/2022] Open
Abstract
Accurate recurrence risk assessment in hormone receptor positive, HER2/neu negative breast cancer is critical to plan precise therapy. CanAssist Breast (CAB) assesses recurrence risk based on tumor biology using artificial intelligence-based approach. We report CAB risk assessment correlating with disease outcomes in multiple clinically high- and low-risk subgroups. In this retrospective cohort of 925 patients [median age-54 (22–86)] CAB had hazard ratio (HR) of 3 (1.83–5.21) and 2.5 (1.45–4.29), P = 0.0009) in univariate and multivariate analysis. CAB's HR in sub-groups with the other determinants of outcome, T2 (HR: 2.79 (1.49–5.25), P = 0.0001); age [< 50 (HR: 3.14 (1.39–7), P = 0.0008)]. Besides application in node-negative patients, CAB's HR was 2.45 (1.34–4.47), P = 0.0023) in node-positive patients. In clinically low-risk patients (N0 tumors up to 5 cms) (HR: 2.48 (0.79–7.8), P = 0.03) and with luminal-A characteristics (HR: 4.54 (1–19.75), P = 0.004), CAB identified >16% as high-risk with recurrence rates of up to 12%. In clinically high-risk patients (T2N1 tumors (HR: 2.65 (1.31–5.36), P = 0.003; low-risk DMFS: 92.66 ± 1.88) and in women with luminal-B characteristics (HR: 3.24; (1.69–6.22), P < 0.0001; low-risk DMFS: 93.34 ± 1.34)), CAB identified >64% as low-risk. Thus, CAB prognostication was significant in women with clinically low- and high-risk disease. The data imply the use of CAB for providing helpful information to stratify tumors based on biology incorporated with clinical features for Indian patients, which can be extrapolated to regions with similarly characterized patients, South-East Asia. Prospective analysis of CAB prognostication in a retrospective cohort of ethnic Indian origin. CAB based prognostication was significant in women aged above and below 50 years. In clinically high-risk and women with luminal B features greater numbers were low-risk. In clinically low-risk and women with luminal A features greater numbers were high-risk.
Collapse
Affiliation(s)
| | | | - S P Somashekhar
- Manipal Hospital and Comprehensive Cancer Centre, Bengaluru, Karnataka, India
| | - Aparna Gunda
- OncoStem Diagnostics, Bengaluru, Karnataka, India
| | - Gurpreet Singh
- Post-Graduation Institute of Medical Education and Research, Chandigarh, India
| | - Amanjit Bal
- Post-Graduation Institute of Medical Education and Research, Chandigarh, India
| | - Siddhant Khare
- Post-Graduation Institute of Medical Education and Research, Chandigarh, India
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Shah T, Vijay DG, Shah N, Patel B, Patel S, Khant N, Gothwal K. Chemoport Insertion-Less Is More. Indian J Surg Oncol 2021; 12:139-145. [PMID: 33814844 DOI: 10.1007/s13193-020-01265-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Accepted: 11/24/2020] [Indexed: 12/01/2022] Open
Abstract
Implantable chemoport is a very useful device for long-term venous access for infusion of chemotherapeutic drugs and other agents. There are few studies from resource poor countries reporting complications of chemoport. The aim of the present study is to evaluate the feasibility of chemoport insertion without image guidance and by closed technique without direct visualisation of a major vein (mainly IJV) and to study the complications associated with the procedure. This was a prospective observational study which analysed 263 patients who underwent chemoport insertion. The medical records of these patients were analysed for the patient characteristics, diagnosis, port-related complications, and their management. A total of 263 patients who were harbouring either locoregionally advanced or metastatic tumour requiring either chemotherapy or targeted treatment or both were included in the study. In total, 133 (50.57%) were female patients and 130 were male patients (49.43%). A total of 236 patients (89.73%) underwent port insertion procedures under local anaesthesia. None of the patients had any major intra-operative complications. Postoperatively, 4 patients (1.52%) were found to have port catheter malposition; 3 out of this 4 were corrected under IITV guidance as a second procedure under local anaesthesia only. One patient (0.38%) required formal removal and replacement of port. Four patients (1.52%) developed IJV thrombosis requiring port removal and anti-coagulation. One patient (0.38%) developed thrombus in the right atrium. There were 2 port site infections (0.74%) requiring port removal (SSI cat. 5). Low complication rates of port insertion were observed in the present, large, prospective study. Complication rates may be further reduced by using a well-designed procedure, experienced surgeons, an aseptic environment, ultrasound-guided puncture, and fluoroscopy with contrast media. Supplementary Information The online version contains supplementary material available at 10.1007/s13193-020-01265-6.
Collapse
Affiliation(s)
| | - D G Vijay
- HCG Cancer Hospital, Ahmedabad, India
| | | | | | | | | | | |
Collapse
|
3
|
Somashekhar SP, Zaveri S, Vijay DG, Dattatreya PS, Kumar R, Islahi F, Bahl C. Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort. JCO Glob Oncol 2020; 6:1363-1369. [PMID: 32897733 PMCID: PMC7529538 DOI: 10.1200/go.20.00250] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE There are new advancements in the modulation of the treatment of patients with early-stage breast cancer, including the use of several molecular profiling tests to identify or select those patients who require additional adjuvant chemotherapy together with hormonal therapy on the basis of a recurrence score. One such tool is EndoPredict (Myriad Genetics; Salt Lake City, UT), which provides support in clinical decision making. The objective of this analysis was to study the landscape of absolute chemotherapy benefit and the likelihood of recurrence within 5 to 15 years in Indian patients with breast cancer who are undergoing EndoPredict testing. PATIENTS AND METHODS This study included 308 patients with hormone-positive, human epidermal growth factor receptor 2–negative early breast cancer. Their postsurgical blocks were analyzed using the EndoPredict test. The MEDCALC statistical tool (Panum Education; Seoul, Republic of Korea) was used to estimate the correlation coefficient and to conduct multiple regression analysis. RESULTS On the basis of the EndoPredict EPclin Risk Score, 52.12% of patients were classified as being in the low-risk category and could safely forgo adjuvant chemotherapy. For every unit increase in the EPclin Risk Score, the percentage increase in absolute chemotherapy benefit was 6.82%. Similarly, the correlation between the likelihood of recurrence within 5 to 15 years and the EPclin Risk Score suggested that there is a 10.34% increase in recurrence for each unit of EPclin Risk Score. CONCLUSION The EPclin Risk Score has good prognostic and predictive power; it also provides the range of chemotherapy benefit for Indian patients.
Collapse
Affiliation(s)
- S P Somashekhar
- Manipal Comprehensive Cancer Care Centre, Manipal Hospital, Bengaluru, Karnataka, India
| | - Shabber Zaveri
- Manipal Comprehensive Cancer Care Centre, Manipal Hospital, Bengaluru, Karnataka, India
| | | | | | - Rajeev Kumar
- Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, Delhi, India
| | - Fatma Islahi
- Department of Clinical Genomics and Bioinformatics, Positive Bioscience, Kohinoor Mall, Kurla West, Mumbai, India
| | - Charu Bahl
- Department of Clinical Genomics and Bioinformatics, Positive Bioscience, Kohinoor Mall, Kurla West, Mumbai, India
| |
Collapse
|
4
|
Shah T, Shah N, Vijay DG, Patel B, Patel S. Male Breast Cancer: Current Trends-a Tertiary Care Centre Experience. Indian J Surg Oncol 2020; 11:7-11. [PMID: 32205960 DOI: 10.1007/s13193-019-01021-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Accepted: 11/13/2019] [Indexed: 10/25/2022] Open
Abstract
Male breast cancer is a rare tumour in all parts of the world. About 1% of all breast cancers occur in men. Occurrence of male breast cancer peaks at age 71 years. Familial cases usually have BRCA2 rather than BRCA1 mutations. Presentation is usually a lump or nipple inversion, but is often late, with more than 40% of individuals having stage III or IV disease. We retrospectively reviewed 25 male patients with breast cancer who came to the HCG Cancer Centre, Ahmedabad between 2014 and 2018, and their demographic details, tumor profile, and radiological, histopathological as well as luminal profile findings were studied. The average age at presentation and detection of male breast cancer was 61.08 years. Incidence of male ca. breast over these 4 years was 4.75/year which had a significant increase compared with our own data in the last 8 years (3/year). Male to female ratio for ca. breast was 1:61. One out of 25 (4%) patients had gynaecomastia. The most common histology was invasive ductal carcinoma-not otherwise specified with none of the patients having lobular carcinoma. Majority of patients were ER/PR positive and HER-2 negative. Male breast cancer is having a rising incidence, which in our study is 1.56%. Males have relatively older age at presentation and stage-by-stage treatment remains the same. Males are more likely to be having prognostically favourable luminal subtypes. Male breast cancer in Indian population is currently experiencing an increasing trend. Improved awareness amongst patients and high index of suspicion by the clinicians along with accurate diagnostic techniques help detect the disease at an earlier stage culminating into prolonged overall and disease-free survival.
Collapse
Affiliation(s)
- Tanay Shah
- Surgical Oncology, HCG Cancer Hospital, S.g. Road, Ahmedabad, GJ 380060 India
| | - Niket Shah
- Surgical Oncology, HCG Cancer Hospital, S.g. Road, Ahmedabad, GJ 380060 India
| | - D G Vijay
- Surgical Oncology, HCG Cancer Hospital, S.g. Road, Ahmedabad, GJ 380060 India
| | - Bhavesh Patel
- Surgical Oncology, HCG Cancer Hospital, S.g. Road, Ahmedabad, GJ 380060 India
| | - Samir Patel
- Surgical Oncology, HCG Cancer Hospital, S.g. Road, Ahmedabad, GJ 380060 India
| |
Collapse
|
5
|
Dodiya HG, Brahmbhatt AP, Khatri PK, Kaushal AM, Vijay DG. Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study. J Cancer Res Ther 2016; 11:612-6. [PMID: 26458590 DOI: 10.4103/0973-1482.146056] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Locally advanced breast cancer (LABC) remains major clinical issue with regard to selection and duration of therapy since many years. Neoadjuvant chemotherapy (NACT) is multimodality program, established to treat LABC. Many research tasks are ongoing to develop specific neoadjuvant chemotherapy regimen with specific duration to improve long-term control of LABC. PATIENTS AND METHODS Forty-seven patients diagnosed with LABC were Included and analyzed to compare the outcomes [pathological complete response (pCR), clinical response, overall response rate (ORR), disease control rate, overall survival and progression-free survival]. These patients treated with either combination of anthracycline and taxane-based chemotherapy or anthracycline-based chemotherapy. RESULTS There was no any statistical significance with respect to demographic data treated of patients between two arms (P>0.05). Patients underwent TAC chemotherapy had pCR 20.8% whereas FAC/FEC chemotherapy patients had pCR 13% (P=0.48). Higher ORR was noted in TAC chemotherapy arm (75%) when compared with FAC/FEC chemotherapy arm (60.9%) (P=0.29). The study also shows better disease control rate in TAC chemotherapy arm (95.8%) as compared to FAC/FEC chemotherapy arm (82.6%). There was no statistical significance in overall survival (P=0.31) and progression-free survival (P=0.51) between two arms. CONCLUSION Despite of the superiority of combination of anthracycline and taxane-based chemotherapy over the anthracycline-based chemotherapy in the present study, further pivotal studies should be conducted to confirm the combination of anthracycline and taxane-based chemotherapy as a better neoadjuvant regimen for treatment of LABC tumors.
Collapse
Affiliation(s)
- Hardik G Dodiya
- Department of Clinical Research and Development, Aastha Oncology Associates, HCG-Medisurge Hospitals Private Limited, Ahmedabad, Gujarat, India
| | | | | | | | | |
Collapse
|
6
|
Dodiya H, Patel A, Patel D, Kaushal A, Vijay DG. Study of hormone receptors and epidermal growth factor expression in invasive breast cancers in a cohort of Western India. Indian J Clin Biochem 2013; 28:403-9. [PMID: 24426244 DOI: 10.1007/s12291-012-0294-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2012] [Accepted: 12/15/2012] [Indexed: 12/19/2022]
Abstract
The objective of study was to evaluate and correlate the pathological characteristics of breast cancer patients with estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2/neu) detected by immunohistochemistry and/or fluorescent in situ hybridization method. We have conducted 2 year study of 204 cases of breast cancer at HCG-Medisurge Hospitals, Ahmedabad from 2009 to 2011. Significant correlation was found in ER and PR expression whereas no correlation was found in hormonal receptors and Her2/neu expression. ER and PR positivity increased with advancing age in breast carcinoma patients while not affecting Her2/neu expression. The expression of hormone receptors were higher in infiltrating lobular carcinoma and infiltrating duct carcinoma subtypes of breast carcinoma as compared to other subtypes such medullary and in situ carcinoma. High-grade carcinoma patients were predominantly ER/PR negative and Her2/neu positive as compared to lower grade breast carcinoma whereas high-stage carcinoma patients were ER/PR positive and Her2/neu positive as compared to lower stage breast carcinoma.
Collapse
Affiliation(s)
- Hardik Dodiya
- Department of Clinical Research and Development, Aastha Oncology Associates, HCG-Medisurge Hospitals Private Limited, Ahmedabad, 380006 Gujarat India
| | - Amit Patel
- Department of Clinical Research and Development, Aastha Oncology Associates, HCG-Medisurge Hospitals Private Limited, Ahmedabad, 380006 Gujarat India
| | - Dipal Patel
- Department of Clinical Research and Development, Aastha Oncology Associates, HCG-Medisurge Hospitals Private Limited, Ahmedabad, 380006 Gujarat India
| | - Ashish Kaushal
- Department of Clinical Research and Development, Aastha Oncology Associates, HCG-Medisurge Hospitals Private Limited, Ahmedabad, 380006 Gujarat India
| | - D G Vijay
- Department of Clinical Research and Development, Aastha Oncology Associates, HCG-Medisurge Hospitals Private Limited, Ahmedabad, 380006 Gujarat India
| |
Collapse
|